Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Merck, Eisai Provide Update On Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA; Combination Did Not Result In An Overall Survival Benefit For Patients

Author: Benzinga Newsdesk | August 25, 2023 06:19am

At the second analysis, KEYTRUDA plus LENVIMA did not demonstrate an improvement in OS compared to KEYTRUDA plus placebo, and the likelihood of reaching the protocol-specified threshold for statistical significance for OS was evaluated by Merck and Eisai and deemed to be low. Accordingly, the study will be closed, and the companies are informing investigators of this decision.

Posted In: ESAIY MRK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist